Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
Introduction:Pancreatic cancer is the seventh leading cause of cancer-related death worldwide, and surgical resection with radical intent remains the only potentially curative treatment option today. However, borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC) stand in the gray area be...
| Authors: | ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2022 |
| Country: | España |
| Institution: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repository: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:2445/192186 |
| Online Access: | https://hdl.handle.net/2445/192186 |
| Access Level: | Open access |
| Keyword: | Càncer de pàncrees Cirurgia Tractament adjuvant del càncer Pancreas cancer Surgery Adjuvant treatment of cancer |
| _version_ | 1878740709587025920 |
|---|---|
| author | Secanella Medayo, Luis |
| author2 | Busquets, Juli Peláez, Núria Sorribas, María Laquente, Berta Ruiz, Sandra Carnaval, Thiago Videla, Sebastià Fabregat, Juan |
| author2_role | author author author author author author author author |
| author_browse | Busquets, Juli Carnaval, Thiago Fabregat, Juan Laquente, Berta Peláez, Núria Ruiz, Sandra Secanella Medayo, Luis Sorribas, María Videla, Sebastià |
| author_facet | Secanella Medayo, Luis Busquets, Juli Peláez, Núria Sorribas, María Laquente, Berta Ruiz, Sandra Carnaval, Thiago Videla, Sebastià Fabregat, Juan |
| author_role | author |
| collection | Recercat. Dipósit de la Recerca de Catalunya |
| description | Introduction:Pancreatic cancer is the seventh leading cause of cancer-related death worldwide, and surgical resection with radical intent remains the only potentially curative treatment option today. However, borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC) stand in the gray area between the resectable and unresectable disease since they are technically resectable but have a high probability of incomplete exeresis. Neoadjuvant treatment (NAT) plays an important role in ensuring resection success.Different survival prognostic factors for BR-PDAC have been well described, but evidence on the predictive factors associated with resection after NAT is scarce. This study aims to study if CA 19-9 plasmatic levels and the tumor anatomical relationship with neighboring vascular structures are prognostic factors for resection and survival (both Overall Survival and Progression-Free Survival) in patients with type A BR-PDAC. Methods:This will be a retrospective cohort study using data from type A BR-PDAC patients who received NAT in the Bellvitge University Hospital. The observation period is from January 2010 until December 2019; patients must have a minimum 12-month follow-up. Patients will be classified according to the MD Anderson Cancer Center criteria for BR-PDAC. Discussion:Patients with BR-PDAC have a high risk for a margin-positive resection. Serum Carbohydrate Antigen 19-9 plasmatic levels and vascular involvement stand out as disease-related prognostic factors.This study will provide valuable information on the prognostic factors associated with resection. We will exclude locally advanced tumors and expect this approach to provide more realistic resection rates without selecting those patients that undergo surgical exploration. However, focusing on an anatomical definition may limit the results' generalizability. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_d7ffc8176d7f6bbcee184a90cb0b2ed2 |
| institution | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:recercat.cat:2445/192186 |
| publishDate | 2022 |
| publishDateSort | 2022 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| publisherStr | Ovid Technologies (Wolters Kluwer Health) |
| reponame_str | Recercat. Dipósit de la Recerca de Catalunya |
| spelling | Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study Secanella Medayo, Luis Busquets, Juli Peláez, Núria Sorribas, María Laquente, Berta Ruiz, Sandra Carnaval, Thiago Videla, Sebastià Fabregat, Juan Càncer de pàncrees Cirurgia Tractament adjuvant del càncer Pancreas cancer Surgery Adjuvant treatment of cancer Introduction:Pancreatic cancer is the seventh leading cause of cancer-related death worldwide, and surgical resection with radical intent remains the only potentially curative treatment option today. However, borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC) stand in the gray area between the resectable and unresectable disease since they are technically resectable but have a high probability of incomplete exeresis. Neoadjuvant treatment (NAT) plays an important role in ensuring resection success.Different survival prognostic factors for BR-PDAC have been well described, but evidence on the predictive factors associated with resection after NAT is scarce. This study aims to study if CA 19-9 plasmatic levels and the tumor anatomical relationship with neighboring vascular structures are prognostic factors for resection and survival (both Overall Survival and Progression-Free Survival) in patients with type A BR-PDAC. Methods:This will be a retrospective cohort study using data from type A BR-PDAC patients who received NAT in the Bellvitge University Hospital. The observation period is from January 2010 until December 2019; patients must have a minimum 12-month follow-up. Patients will be classified according to the MD Anderson Cancer Center criteria for BR-PDAC. Discussion:Patients with BR-PDAC have a high risk for a margin-positive resection. Serum Carbohydrate Antigen 19-9 plasmatic levels and vascular involvement stand out as disease-related prognostic factors.This study will provide valuable information on the prognostic factors associated with resection. We will exclude locally advanced tumors and expect this approach to provide more realistic resection rates without selecting those patients that undergo surgical exploration. However, focusing on an anatomical definition may limit the results' generalizability. Ovid Technologies (Wolters Kluwer Health) https://hdl.handle.net/2445/192186 |
| spellingShingle | Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study Secanella Medayo, Luis Càncer de pàncrees Cirurgia Tractament adjuvant del càncer Pancreas cancer Surgery Adjuvant treatment of cancer |
| status_str | publishedVersion |
| title | Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study |
| title_full | Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study |
| title_fullStr | Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study |
| title_full_unstemmed | Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study |
| title_short | Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study |
| title_sort | Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study |
| topic | Càncer de pàncrees Cirurgia Tractament adjuvant del càncer Pancreas cancer Surgery Adjuvant treatment of cancer |
| topic_facet | Càncer de pàncrees Cirurgia Tractament adjuvant del càncer Pancreas cancer Surgery Adjuvant treatment of cancer |
| url | https://hdl.handle.net/2445/192186 |